XFOR
VENTE TOTALE: 47 436 titres (~210 829,30 $ US)
- Insiders
- Craig Adam R
- Total bought
- —
- Total sold
- $210,829
- Last activity
- 2026-08-12
- Last synced
-
2026-08-21 23:36:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-16
XFOR presents a deeply conflicted profile: while short-term liquidity is adequate (75) and a Zacks Rank #2 upgrade provides a moderate catalyst signal (55), the fundamental health score of 25 reflects severe structural…
The first sentence of the analysis written for XFOR on 2026-08-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 82.2% | 68.8% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | -200.2% | -1109.6% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | -196.5% | -1078.5% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | -247.4% | -1423.6% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | -225.4% | -1452.5% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | -225.6% | -1464.6% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | -225.6% | -1464.6% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | -225.6% | -1464.6% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 10.156 | 3.412 | 5.340 | 5.764 | 6.267 | |
| Quick Ratio | 9.982 | 3.326 | 5.340 | 5.764 | 6.267 | |
| Solvency Ratio | -0.748 | -0.295 | -1.048 | -1.145 | -1.645 | |
| Cash Ratio | 8.427 | 1.694 | 4.340 | 5.452 | 5.832 | |
| Price To Earnings Ratio | -2.139 | -3.937 | -1.474 | -0.653 | -0.575 | |
| Price To Earnings Growth Ratio | 0.032 | 0.059 | 0.024 | 0.011 | -0.020 | |
| Forward Price To Earnings Growth Ratio | 0.032 | 0.059 | 0.024 | 0.011 | -0.020 | |
| Price To Earnings Diluted Ratio | -2.139 | -3.937 | -1.474 | -0.653 | -0.575 | |
| Price To Earnings Diluted Growth Ratio | 0.032 | 0.059 | 0.024 | 0.011 | -0.020 | |
| Price To Book Ratio | 0.908 | 6.660 | 2.918 | 0.852 | 0.915 | |
| Price To Sales Ratio | 4.818 | 57.690 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -1.909 | -1.067 | -1.544 | -0.817 | -0.824 | |
| Price To Operating Cash Flow Ratio | -1.976 | -1.127 | -1.545 | -0.818 | -0.832 | |
| Debt To Assets Ratio | 0.266 | 0.533 | 0.396 | 0.247 | 0.340 | |
| Debt To Equity Ratio | 0.415 | 3.525 | 1.141 | 0.519 | 0.618 | |
| Debt To Capital Ratio | 0.293 | 0.779 | 0.533 | 0.342 | 0.382 | |
| Long Term Debt To Capital Ratio | 0.291 | 0.773 | 0.516 | 0.304 | 0.340 | |
| Financial Leverage Ratio | 1.559 | 6.612 | 2.882 | 2.101 | 1.819 | |
| Working Capital Turnover Ratio | 0.223 | 0.029 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -3.324 | -3.982 | -4.222 | -3.454 | -5.056 | |
| Operating Cash Flow Sales Ratio | -2.438 | -51.193 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.035 | 1.056 | 1.001 | 1.001 | 1.009 | |
| Debt Service Coverage Ratio | -7.779 | -3.180 | -16.440 | -16.835 | -15.087 | |
| Interest Coverage Ratio | -9.789 | -4.152 | -18.612 | -21.931 | -20.689 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | -58.633 | -37.917 | |
| Operating Cash Flow Coverage Ratio | -1.108 | -1.676 | -1.656 | -2.007 | -1.782 | |
| Capital Expenditure Coverage Ratio | -28.539 | -17.868 | -1,608.533 | -748.563 | -115.293 | |
| Dividend Paid And Capex Coverage Ratio | -28.539 | -17.868 | -1,608.533 | -748.563 | -115.293 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -0.426 | -6.161 | -1.140 | 0.226 | -0.204 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 82.2% | ▲13.4% | ▲52.0% |
| Ebit Margin | -200.2% | ▲909.4% | ▲61.8% |
| Ebitda Margin | -196.5% | ▲881.9% | ▲58.5% |
| Operating Profit Margin | -247.4% | ▲1176.1% | ▲86.8% |
| Pretax Profit Margin | -225.4% | ▲1227.0% | ▲110.1% |
| Continuous Operations Profit Margin | -225.6% | ▲1239.0% | ▲112.5% |
| Net Profit Margin | -225.6% | ▲1239.0% | ▲112.5% |
| Bottom Line Profit Margin | -225.6% | ▲1239.0% | ▲112.5% |
| Current Ratio | 10.156 | ▲6.744 | ▲3.968 |
| Quick Ratio | 9.982 | ▲6.655 | ▲3.846 |
| Solvency Ratio | -0.748 | ▼-0.453 | ▲0.228 |
| Cash Ratio | 8.427 | ▲6.733 | ▲3.278 |
| Price To Earnings Ratio | -2.139 | ▲1.798 | ▼-0.383 |
| Price To Earnings Growth Ratio | 0.032 | ▼-0.026 | ▲0.011 |
| Forward Price To Earnings Growth Ratio | 0.032 | ▼-0.026 | ▲0.011 |
| Price To Earnings Diluted Ratio | -2.139 | ▲1.798 | ▼-0.383 |
| Price To Earnings Diluted Growth Ratio | 0.032 | ▼-0.026 | ▲0.011 |
| Price To Book Ratio | 0.908 | ▼-5.752 | ▼-1.543 |
| Price To Sales Ratio | 4.818 | ▼-52.872 | ▼-7.684 |
| Price To Free Cash Flow Ratio | -1.909 | ▼-0.842 | ▼-0.677 |
| Price To Operating Cash Flow Ratio | -1.976 | ▼-0.849 | ▼-0.716 |
| Debt To Assets Ratio | 0.266 | ▼-0.267 | ▼-0.090 |
| Debt To Equity Ratio | 0.415 | ▼-3.111 | ▼-0.829 |
| Debt To Capital Ratio | 0.293 | ▼-0.486 | ▼-0.172 |
| Long Term Debt To Capital Ratio | 0.290 | ▼-0.482 | ▼-0.154 |
| Financial Leverage Ratio | 1.559 | ▼-5.053 | ▼-1.435 |
| Working Capital Turnover Ratio | 0.223 | ▲0.194 | ▲0.173 |
| Operating Cash Flow Ratio | -3.324 | ▲0.657 | ▲0.683 |
| Operating Cash Flow Sales Ratio | -2.438 | ▲48.755 | ▲8.288 |
| Free Cash Flow Operating Cash Flow Ratio | 1.035 | ▼-0.021 | ▲0.015 |
| Debt Service Coverage Ratio | -7.779 | ▼-4.598 | ▲4.085 |
| Interest Coverage Ratio | -9.789 | ▼-5.637 | ▲5.246 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲19.310 |
| Operating Cash Flow Coverage Ratio | -1.108 | ▲0.569 | ▲0.538 |
| Capital Expenditure Coverage Ratio | -28.539 | ▼-10.671 | ▲475.220 |
| Dividend Paid And Capex Coverage Ratio | -28.539 | ▼-10.671 | ▲475.220 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -0.426 | ▲5.735 | ▲1.115 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $169.2M | $147.5M | $149.1M | $63.1M | $59.0M | |
| Enterprise value | $29.4M | $169.9M | $108.2M | -$20.2M | $17.0M | |
| EV / Sales | 0.84x | 66.44x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -0.34x | -1.30x | -1.12x | 0.26x | -0.24x | |
| EV / Free cash flow | -0.33x | -1.23x | -1.12x | 0.26x | -0.24x | |
| EV / EBITDA | -0.43x | -6.16x | -1.14x | 0.23x | -0.20x | |
| Net debt / EBITDA | 2.02x | -0.81x | 0.43x | 0.93x | 0.51x | |
| Current ratio | 10.16x | 3.41x | 5.34x | 5.76x | 6.27x | |
| Income quality | 1.08x | 3.50x | 0.95x | 0.82x | 0.80x | |
| Graham net-net | $4 | -$3 | $3 | $19 | $34 | |
| Tax burden | 100.1% | 100.8% | 100.1% | 100.0% | 100.0% | |
| Interest burden | 112.6% | 130.9% | 106.1% | 104.4% | 104.3% | |
| Working capital | $235.8M | $79.3M | $99.2M | $106.4M | $73.9M | |
| Invested capital | $264.0M | $111.5M | $123.0M | $132.0M | $101.4M | |
| Return on assets | -27.3% | -25.6% | -68.7% | -60.3% | -75.7% | |
| Operating ROA | -39.8% | -24.8% | -71.0% | -64.2% | -62.8% | |
| Return on tangible assets | -30.0% | -31.4% | -77.9% | -67.9% | -88.9% | |
| Return on equity | -42.5% | -169.1% | -198.0% | -126.8% | -137.7% | |
| Return on invested capital | -32.7% | -31.7% | -85.7% | -64.5% | -71.7% | |
| Return on capital employed | -32.8% | -32.1% | -86.4% | -65.7% | -73.0% | |
| Earnings yield | -46.8% | -25.4% | -67.8% | -148.8% | -150.4% | |
| Free cash flow yield | -52.4% | -93.7% | -64.8% | -122.4% | -121.3% | |
| Capex / Op. cash flow | -3.5% | -5.6% | -0.1% | -0.1% | -0.9% | |
| Capex / Depreciation | 234.9% | 920.4% | 14.3% | 20.1% | 32.5% | |
| Capex / Sales | 8.5% | 286.5% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 123.9% | 2405.9% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 205.7% | 3192.9% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 12.2% | 320.8% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 9.2% | 18.7% | 11.8% | 11.2% | 14.8% | |
| Days sales outstanding | 6d | 244d | 0d | 0d | 0d | |
| Days payables outstanding | 332d | 3948d | 0d | 0d | 826d | |
| Operating cycle | 267d | 1534d | 0d | 0d | 0d | |
| Cash conversion cycle | -65d | -2414d | 0d | 0d | -826d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+14.7%EV / Sales ▼-98.7%EV / EBITDA ▲+93.1%EV / Op. cash flow ▲+0.954Earnings yield ▼-0.214
Profitability
Return on equity ▲+1.266Return on assets ▼-0.017Return on invested capital ▼-0.010Return on capital employed ▼-0.008Operating ROA ▼-0.150Income quality ▼-2.414Tax burden ▼-0.008
Efficiency
Days sales outstanding ▼-238.138Days payables outstanding ▼-3615.863Operating cycle ▼-1266.951Cash conversion cycle ▲+2348.911Capex / Sales ▼-2.780R&D / Sales ▼-29.872
Balance-sheet strength
Current ratio ▲+6.744Net debt / EBITDA ▲+2.837Working capital ▲+156522000.000Invested capital ▲+152522000.000Intangibles / Total assets ▼-0.095
Change over 5 years
Valuation
Market cap ▲+186.9%EV / Sales n/aEV / EBITDA ▼-108.9%EV / Op. cash flow ▼-0.104Earnings yield ▲+1.036
Profitability
Return on equity ▲+0.952Return on assets ▲+0.484Return on invested capital ▲+0.390Return on capital employed ▲+0.402Operating ROA ▲+0.230Income quality ▲+0.282Tax burden +0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▼-493.992Operating cycle n/aCash conversion cycle ▲+761.229Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+3.889Net debt / EBITDA ▲+1.520Working capital ▲+161965000.000Invested capital ▲+162582000.000Intangibles / Total assets ▼-0.056
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-11 X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here''s Why X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 2026-08-06 X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the second quarter ended June 30, 2026 and provided a corporate update.
- 2026-08-03 X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 12,000 shares of X4''s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4''s Compensation Committee of the Board of Directors.
- 2026-07-07 X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 6, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 750,000 shares of X4''s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4''s Compensation Committee of the Board of Directors.
- 2026-07-01 X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly Gold to the Company''s Board of Directors effective July 1, 2026, adding strong strategic and financial expertise. Ms. Gold will serve as an independent director and member of the Audit Committee.
- 2026-06-01 X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on May 29, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 160,000 shares of X4''s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4''s Compensation Committee of the Board of Directors.
- 2026-05-27 X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 3:45 p.m. ET. A link to the live and archived webcast may be accessed on X4 Pharmaceuticals'' website under the Investors section: Events and Presentations.
- 2026-05-20 Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here''s Why It''s a ''Buy'' Now X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 2026-05-18 X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here''s What You Should Know X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).